Protection of trigonelline on experimental diabetic peripheral neuropathy

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Zhou, Ji Yin ^a   Zhou, Shi Wen ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE P38; SITAGLIPTIN; SUPEROXIDE DISMUTASE; TRIGONELLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALE; NERVE CONDUCTION; NOCICEPTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

EID: 84871434393     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/164219     Document Type: Article

References (52)

1. Pinzur M. S., Diabetic Peripheral Neuropathy. Foot and Ankle Clinics 2011 16 2 345 349 2-s2.0-79956055449 10.1016/j.fcl.2011.01.002
2. Boulton A. J. M., Vinik A. I., Arezzo J. C., Bril V., Feldman E. L., Freeman R., Malik R. A., Maser R. E., Sosenko J. M., Ziegler D., Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005 28 4 956 962 2-s2.0-20144389536 10.2337/diacare.28.4.956 (Pubitemid 40434506)
3. Habib A. A., Brannagan T. H. III, Therapeutic strategies for diabetic neuropathy. Current Neurology and Neuroscience Reports 2010 10 2 92 100 2-s2.0-77953542766 10.1007/s11910-010-0093-7
4. Chang C. L., Lin C. S., Phytochemical composition, antioxidant activity, and neuroprotective effect of terminalia chebula retzius extracts. Evidence-Based Complementary and Alternative Medicine 2012 2012 7 10.1155/2012/125247 125247
5. Xian Y. F., Lin Z. X., Mao Q. Q., Bioassay-guided isolation of neuroprotective compounds from Uncaria rhynchophylla against beta-amyloid-induced neurotoxicity. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 802625 10.1155/2012/802625
6. Zhou J., Chan L., Zhou S., Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Current Medicinal Chemistry 2012 19 21 3523 3531
7. Zia T., Hasnain S. N., Hasan S. K., Evaluation of the oral hypoglycaemic effect of Trigonella foenum-graecum L. (methi) in normal mice. Journal of Ethnopharmacology 2001 75 2-3 191 195 2-s2.0-0035070501 10.1016/S0378-8741(01) 00186-6 (Pubitemid 32297733)
8. Thakran S., Siddiqui M. R., Baquer N. Z., Trigonella foenum graecum seed powder protects against histopathological abnormalities in tissues of diabetic rats. Molecular and Cellular Biochemistry 2004 266 1-2 151 159 2-s2.0-9444283831 10.1023/B:MCBI.0000049153.14295.0d (Pubitemid 39562316)
9. Moorthy R., Prabhu K., Murthy P., Studies on the isolation and effect of orally active hypoglycemic principle from the seeds of fenugreek (Trigonella foenum graecum). Diabetes Bulletin 1989 9 69 72
10. Mishkinsky J., Joseph B., Sulman F. G., Hypoglycaemic effect of trigonelline. The Lancet 1967 2 7529 1311 1312 2-s2.0-0014208934
11. y mice. Current Medicinal Chemistry 2010 17 20 2196 2202 2-s2.0-77955624213 10.2174/092986710791299902
12. Yoshinari O., Sato H., Igarashi K., Anti-diabetic effects of pumpkin and its components, trigonelline and nicotinic acid, on goto-kakizaki rats. Bioscience, Biotechnology and Biochemistry 2009 73 5 1033 1041 2-s2.0-67049159773 10.1271/bbb.80805
13. Van Dijk A. E., Olthof M. R., Meeuse J. C., Seebus E., Heine R. J., Van Dam R. M., Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 2009 32 6 1023 1025 2-s2.0-66549126196 10.2337/dc09-0207
14. Olthof M. R., Van Dijk A. E., Deacon C. F., Heine R. J., Van Dam R. M., Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones. Nutrition and Metabolism 2011 8, article 10 2-s2.0-79551642386 10.1186/1743-7075-8-10
15. Bakuradze T., Lang R., Hofmann T., Stiebitz H., Bytof G., Lantz I., Baum M., Eisenbrand G., Janzowski C., Antioxidant effectiveness of coffee extracts and selected constituents in cell-free systems and human colon cell lines. Molecular Nutrition and Food Research 2010 54 12 1734 1743 2-s2.0-78649836179 10.1002/mnfr.201000147
16. Yen W. J., Wang B. S., Chang L. W., Duh P. D., Antioxidant properties of roasted coffee residues. Journal of Agricultural and Food Chemistry 2005 53 7 2658 2663 2-s2.0-16344386399 10.1021/jf0402429 (Pubitemid 40471748)
17. Zhou J., Zhou S., Zeng S., Experimental diabetes treated with trigonelline: effect on beta cell and pancreatic oxidative parameters. Fundamental & Clinical Pharmacology. In press 10.1111/j.1472-8206.2011. 01022.x
18. Zhou J. Y., Zhou S. W., Zeng S. Y., Zhou J. Y., Jiang M. J., He Y., Hypoglycemic and hypolipidemic effects of ethanolic extract of mirabilis jalapa L. Root on normal and diabetic mice. Evidence-Based Complementary and Alternative Medicine 2012 2012 9 257374 10.1155/2012/257374
19. Harkavyi A., Whitton P. S., Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. British Journal of Pharmacology 2010 159 3 495 501 2-s2.0-76449115696 10.1111/j.1476-5381.2009.00486.x
20. Perry T., Holloway H. W., Weerasuriya A., Mouton P. R., Duffy K., Mattison J. A., Greig N. H., Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Experimental Neurology 2007 203 2 293 301 2-s2.0-33846501672 10.1016/j.expneurol.2006.09.028 (Pubitemid 46157226)
21. Himeno T., Kamiya H., Naruse K., Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011 60 9 2397 2406
22. Bianchi R., Cervellini I., Porretta-Serapiglia C., Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. The Journal of Pharmacology and Experimental Therapeutics 2012 340 1 64 72
23. Liu W. J., Jin H. Y., Lee K. A., Xie S. H., Baek H. S., Park T. S., Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. British Journal of Pharmacology 2011 164 5 1410 1420
24. Jin H. Y., Liu W. J., Park J. H., Baek H. S., Park T. S., Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats. Archives of Medical Research 2009 40 7 536 544 2-s2.0-71649102751 10.1016/j.arcmed.2009.09.005
25. Li Y., Perry T., Kindy M. S., Harvey B. K., Tweedie D., Holloway H. W., Powers K., Shen H., Egan J. M., Sambamurti K., Brossi A., Lahiri D. K., Mattson M. P., Hoffer B. J., Wang Y., Greig N. H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 2009 106 4 1285 1290 2-s2.0-59049087723 10.1073/pnas.0806720106
26. Jolivalt C. G., Fineman M., Deacon C. F., Carr R. D., Calcutt N. A., GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes, Obesity & Metabolism 2011 13 11 990 1000
27. Agthong S., Tomlinson D. R., Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Annals of the New York Academy of Sciences 2002 973 359 362 2-s2.0-0036959463 (Pubitemid 36125035)
28. Jin S. X., Zhuang Z. Y., Woolf C. J., Ji R. R., p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. Journal of Neuroscience 2003 23 10 4017 4022 2-s2.0-0037705314 (Pubitemid 36958419)
29. Zhou J. Y., Zhou S. W., Zhang K. B., Tang J. L., Guang L. X., Ying Y., Xu Y., Zhang L., Li D. D., Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biological and Pharmaceutical Bulletin 2008 31 6 1169 1176 2-s2.0-45749144363 10.1248/bpb.31.1169 (Pubitemid 351871171)
30. Courteix C., Eschalier A., Lavarenne J., Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993 53 1 81 88 2-s2.0-0027286569 10.1016/0304-3959(93)90059-X (Pubitemid 23137271)
31. Sullivan K. A., Hayes J. M., Wiggin T. D., Backus C., Su Oh S., Lentz S. I., Brosius F., Feldman E. L., Mouse models of diabetic neuropathy. Neurobiology of Disease 2007 28 3 276 285 2-s2.0-36148954617 10.1016/j.nbd.2007.07.022 (Pubitemid 350116599)
32. Vincent A. M., Russell J. W., Sullivan K. A., Backus C., Hayes J. M., McLean L. L., Feldman E. L., SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Experimental Neurology 2007 208 2 216 227 2-s2.0-36048968888 10.1016/j.expneurol.2007.07.017 (Pubitemid 350101499)
33. Coppey L. J., Gellett J. S., Davidson E. P., Dunlap J. A., Lund D. D., Yorek M. A., Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001 50 8 1927 1937 2-s2.0-0035430412 (Pubitemid 33641615)
34. Guven A., Yavuz O., Cam M., Comunoglu C., Sevinc O., Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination. International Journal of Neuroscience 2009 119 8 1155 1169 2-s2.0-70350515727 10.1080/00207450902841723
35. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
36. Kedees M. H., Grigoryan M., Guz Y., Teitelman G., Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Molecular and Cellular Endocrinology 2009 311 1-2 69 76 2-s2.0-69249208511 10.1016/j.mce.2009.07.024
37. Zhou J., Zhou S., Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. European Journal of Pharmacology 2010 649 1-3 390 397 2-s2.0-78049235146 10.1016/j.ejphar.2010.09.030
38. Kakkar P., Das B., Viswanathan P. N., A modified spectrophotometric assay of superoxide dismutase. Indian Journal of Biochemistry and Biophysics 1984 21 2 130 132 2-s2.0-0021681627 (Pubitemid 15207169)
39. Draper H. H., Hadley M., Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology 1990 186 421 431 2-s2.0-0025142672 10.1016/0076-6879(90)86135-I (Pubitemid 20279983)
40. Carozzi V., Chiorazzi A., Canta A., Oggioni N., Gilardini A., Rodriguez-Menendez V., Avezza F., Crippa L., Ceresa C., Nicolini G., Bossi M., Cavaletti G., Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. European Journal of Cancer 2009 45 4 656 665 2-s2.0-60149100647 10.1016/j.ejca.2008.10.038
41. Vincent A. M., Russell J. W., Low P., Feldman E. L., Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Reviews 2004 25 4 612 628 2-s2.0-4143110556 10.1210/er.2003-0019 (Pubitemid 39096072)
42. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., Ghezzi P., Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America 2004 101 3 823 828 2-s2.0-9144237424 10.1073/pnas.0307823100 (Pubitemid 38121042)
43. Vincent A. M., Hinder L. M., Pop-Busui R., Feldman E. L., Hyperlipidemia: a new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System 2009 14 4 257 267 2-s2.0-73549119892 10.1111/j.1529-8027.2009. 00237.x
44. White F. A., Jung H., Miller R. J., Chemokines and the pathophysiology of neuropathic pain. Proceedings of the National Academy of Sciences of the United States of America 2007 104 51 20151 20158 2-s2.0-38049150644 10.1073/pnas.0709250104
45. Purves T., Middlemas A., Agthong S., Jude E. B., Boulton A. J. M., Fernyhough P., Tomlinson D. R., A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB Journal 2001 15 13 2508 2514 2-s2.0-0035158585 10.1096/fj.01-0253hyp (Pubitemid 33063180)
46. Temraz T. A., Houssen W. E., Jaspars M., Woolley D. R., Wease K. N., Davies S. N., Scott R. H., A pyridinium derivative from Red Sea soft corals inhibited voltage-activated potassium conductances and increased excitability of rat cultured sensory neurones. BMC Pharmacology 2006 6 10 1 19 2-s2.0-33747202181 10.1186/1471-2210-6-10 (Pubitemid 44227553)
47. Tohda C., Nakamura N., Komatsu K., Hattori M., Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biological and Pharmaceutical Bulletin 1999 22 7 679 682 2-s2.0-0032779216 (Pubitemid 29361698)
48. Tohda C., Kuboyama T., Komatsu K., Search for natural products related to regeneration of the neuronal network. NeuroSignals 2005 14 1-2 34 45 2-s2.0-20944450901 10.1159/000085384 (Pubitemid 40868982)
49. Saini A. K., Kumar A., Sharma S. S., Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. European Journal of Pharmacology 2007 568 1-3 164 172 2-s2.0-34347219785 10.1016/j.ejphar.2007.04.016 (Pubitemid 46994695)
50. Kumar A., Kaundal R. K., Iyer S., Sharma S. S., Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sciences 2007 80 13 1236 1244 2-s2.0-33847334999 10.1016/j.lfs.2006.12.036 (Pubitemid 46329013)
51. Valsecchi A. E., Franchi S., Panerai A. E., Sacerdote P., Trovato A. E., Colleoni M., Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity. Journal of Neurochemistry 2008 107 1 230 240 2-s2.0-51849101592 10.1111/j.1471-4159.2008.05614.x
52. Stavniichuk R., Drel V. R., Shevalye H., Maksimchyk Y., Kuchmerovska T. M., Nadler J. L., Obrosova I. G., Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation. Experimental Neurology 2011 230 1 106 113 2-s2.0-79958027982 10.1016/j.expneurol.2011.04.002